- Skin Cancer
- General Dermatology
- Cosmetic Dermatology
Allergan Inc. has moved its eyelash treatment into the second clinical stage of testing as a therapy for baldness and expects to see data by the middle of next year, Chief Executive Officer David Pyott said.
The product, Latisse, was approved in 2008 to aid in eyelash growth and generated $82 million last year for the Irvine, California-based company. Allergan is currently testing Latisse for men and women against placebo. U.S. regulators generally require three stages of trials before approval.
The tests follow a business model Allergan successfully implemented with Botox, its top-selling product with $1.42 billion in revenue last year. Initially approved for therapeutic uses in 1989, Botox’s wrinkle-smoothing properties were identified as a side effect. The product was then cleared in 2002 as an injection to smooth frown lines between the brows. Latisse is a version of Allergan’s glaucoma drug Lumigan, which was found to stimulate lash growth as a side effect of therapeutic treatment.
Read the complete article on Bloomberg: Botox-Maker Allergan Tests Eyelash Lengthener for Baldness
“That beard is amazing!”
“I’ve been dealing with this for seven years and you were the one the figured it out.”
“I won’t go anywhere else!”
“Thank you for always being so nice to me.”
“Best experience I’ve ever had in a doctor’s office!”
“You have the most wonderful staff!”
“I would take a bullet for Dr Sewell”
If my face ever just falls off...I want YOU to sew it back on!”